Company: DERM
Filing Date: 2025-08-28
Form Type: 424B3
Source: 0001104659-25-084876
Chunk: 12

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 424B3
Chunk 12
---
 income; |

| · | we operate in a heavily regulated industry, and we cannot predict the impact                  
 that any future legislation or administrative or executive action may have on our operations; |

| · | our revenue is dependent mainly upon sales of our dermatology products and            
 any setback relating to the sale of such products could impair our operating results; |

| · | competition could limit our products’ commercial opportunity and profitability, 
 including competition from manufacturers of generic versions of our products;   |

| · | the risk that our products do not achieve broad market acceptance, including 
 by government and third-party payors;                                        |

| · | our reliance on third parties for several aspects of our operations; |

| · | our dependence on our ability to identify, develop, and acquire or in-license     
 products and integrate them into our operations, at which we may be unsuccessful; |

| · | the dependence of the success of our business, including our ability to finance                                              
 our company and generate additional revenue, on the successful commercialization of EmrosiTM and the successful development, 
 regulatory approval and commercialization any future product candidates that we may develop, in-license or acquire;          |

| · | clinical drug development is very expensive, time consuming, and uncertain                                                          
 and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates; |

| · | our competitors could develop and commercialize products similar or identical 
 to ours;                                                                      |

| · | risks related to the protection of our intellectual property and our potential      
 inability to maintain sufficient patent protection for our technology and products; |

| · | our business and operations would suffer in the event of computer system             
 failures, cyber-attacks, or deficiencies in our or our third parties’ cybersecurity; |

| · | the effects of major public health issues, epidemics or pandemics on our 
 product revenues and any future clinical trials;                         |

| · | our potential need to raise additional capital; |

| · | the substantial doubt expressed about our ability to continue as a going 
 concern;                                                                 |

| · | Fortress controls a voting majority of our common stock, which could be detrimental 
 to our other stockholders; and                                                      |

| · | the risks described under the section titled “Risk Factors”                                                                
 in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein. |

The forward-looking statements
contained in this prospectus supplement reflect our views and assumptions as of the effective date of this report.